FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
07/05/2022
Back to search
Official data from USPTO
ORPHALAN INNOVATION FOR ORPHAN DISEASES
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
32
Latest update
07/05/2022
Trademark type
Combined
Nice classes
5, 10, 42, 44
Filing date
09/09/2020
Registration date
12/28/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/28/2021
Last transaction
12/28/2021
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
33
Owner location
FR
Examiner
BETTS, MARCYA
Law office
L60
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a navy blue drop and light purple drop facing each other at its points. To the top left of the drops is a sky blue square with its upper left vertex rounded. To the bottom right of the drops is a purple circle. To the right of the aforementioned elements is the stylized navy blue wording "ORPHALAN" followed by a grey vertical band with the stylized stacked sky blue wording "INNOVATION FOR ORPHAN DISEASES" following the vertical band.
Holders and representatives
Holders
ORPHALAN
Representatives
Heather R. Smith-Carra Banner & Witcoff, Ltd.
Technical classification
Nice Classes
Class 5Class 10Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
diagnostic agents for pharmaceutical use; capsules sold empty for pharmaceutical use; pharmaceutical compounds for the treatment of orphan diseases; pharmaceutical products for the treatment of orphan diseases; chemical preparations for pharmaceutical usefor the treatment of orphan diseases; chemical preparations for medical usefor the treatment of orphan diseases; medicines for the development of treatment for orphan diseases
Class 10
Medical apparatus and instruments for diagnosing and treating orphan diseases; surgical apparatus and instruments; diagnostic apparatus for medical use for diagnosing orphan diseases; immunochemical testing apparatus for medical use; medical testing instruments for diagnosing and treating orphan diseases; substance analysis apparatusmedical devices and medical instruments for the analysis of body fluids; instruments for extraction of liquids from the human bodymedical devices for obtaining body fluid samples; blood testing apparatus; radiology apparatus for medical use; blood testing instrumentsneedles for medical use and veterinary use; resuscitation apparatus; gloves for medical use; gloves for veterinary use; syringes for medical use; fluid injectors for medical use; X-rays for medical use; inhalers for medical use; radiology screens for medical use; containers for applying medicines being medical tubing for administering drugs; special containers for medical waste; probes for medical use; thermometers for medical use; medical casescases fitted for medical instruments; stethoscopes; heart pacemakers; electromagnetic diagnostic imaging apparatus for medical use; needles for medical use
Class 42
Development of pharmaceutical preparations and medicines; development of pharmaceutical products; providing information on clinical studies for pharmaceutical products via an interactive website; evaluation of pharmaceutical products; scientific research in the field of pharmacy; research regarding pharmaceutical products; pharmaceutical research and development; research relating to pharmaceutical products; research and development for the pharmaceutical industry; conducting clinical trials for other in the field of pharmaceutical products; pharmaceutical drug development services; laboratory research services relating to pharmaceutical products; pharmaceutical research services; medical and pharmacological research services; pharmaceutical research and development services; Scientific research for medical purposes; scientific laboratory services; research and development in the field of biotechnology; design and development of medical diagnostic apparatus
Class 44
Advice relating to pharmacyadvice relating to the use of pharmaceuticals for the treatment of orphan diseases; advisory services relating to health; pharmaceutical advice; advice relating to medicines; information to patients on administering medicines; medical information; drug use testing service for medical use; pharmaceutical servicespharmaceutical compounding services and information services relating to diagnosticprophylactic and therapeutic properties of pharmaceutical products; medical testing and analysis services for diagnostic or treatment of orphan disease; health advisory services relating to the use and operation of medical apparatus and instruments for treatment of orphan disease; medical diagnosis of orphan diseases
Publications
History of USPTO decisions and trademark events.
32 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
06/09/2022
FIMP
FINAL DISPOSITION PROCESSED
06/09/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/28/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
12/28/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/12/2021
PUBO
PUBLISHED FOR OPPOSITION
10/12/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/22/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/07/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
09/03/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/03/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
09/03/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
09/03/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/04/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/04/2021
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
08/04/2021
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
04/22/2021
GNFR
FINAL REFUSAL E-MAILED
04/22/2021
CNFR
FINAL REFUSAL WRITTEN
04/22/2021
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
04/10/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/27/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/26/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/26/2021
RFNT
REFUSAL PROCESSED BY IB
03/01/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/08/2021
RFRR
REFUSAL PROCESSED BY MPU
02/08/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/28/2021
CNRT
NON-FINAL ACTION WRITTEN
01/27/2021
DOCK
ASSIGNED TO EXAMINER
01/19/2021
MAFR
APPLICATION FILING RECEIPT MAILED
10/30/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/26/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/22/2020
Continuous trademark protection
Get notified about every new filing that threatens ORPHALAN INNOVATION FOR ORPHAN DISEASES or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.